Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer
Recruiting now · Phase 4
Conditions studied: Breast Cancer
In brief
To investigate the efficacy of albumin-bound paclitaxel combined with carboplatin versus epirubicin combined with docetaxel as neoadjuvant therapy for triple-negative breast cancer.
Key facts
- Study ID
- NCT04136782
- Run by
- Shengjing Hospital
- People needed
- 110
- Starts
- 2021-07-19
- Expected to finish
- 2026-11-30
- Last updated by the study team
- 2021-07-20
Who can join
Age: 18 and older, up to 70. Sex: female. Healthy volunteers: not accepted.
You may qualify if…
- patients developing breast cancer as confirmed by X-ray examination, cancer tissue negative for estrogen receptor, progesterone receptor and HER2, and tumor stage II-III;
- estimated survival > 3 months;
- presence of clinically measurable lesions;
- Karnofsky functional status score ≥ 70;
- normal routine blood test results, normal liver and kidney function, and near normal electrocardiographic manifestations;
- age at 18-70 years.
You may not qualify if…
- stage IV breast cancer patients with bone metastasis or other distant metastasis;
- severe renal insufficiency;
- older adult patients with severe organic diseases such as heart and lung diseases, who are not estimated to be able to tolerate chemotherapy;
- those who have received antineoplastic therapy;
- those who have received neoadjuvant chemotherapy but fail in 2 cycles of neoadjuvant chemotherapy and switch to other regimens or terminate chemotherapy;
- those with history of other malignant tumors;
- those with severe heart, liver, and kidney organ dysfunction or poor health who cannot tolerate chemotherapy, or those who cannot tolerate chemotherapy and switch to other therapeutic regimens;
- those with mental and nervous system diseases who cannot comply with treatment;
- those with dexamethasone intolerance or those who are highly allergic to any drug in neoadjuvant chemotherapy;
- pregnant or lactating women;
- those who are participating in other trials.
Where it is running
- Cancer Hospital Affiliated to Harbin Medical University — Harbin, Heilongjiang, China (enrolling)
- The Second Hospital of Jilin University — Changchun, Jilin, China (enrolling)
- Dalian Municipal Central Hospital — Dalian, Liaoning, China (enrolling)
- Panjin Liaohe Oilfield Gem Flower Hospital — Panjin, Liaoning, China (enrolling)
- Shengjing Hospital of China Medical University — Shenyang, Liaoning, China (enrolling)
- The Fourth Affiliated Hospital of China Medical University — Shenyang, Liaoning, China (enrolling)
- Liaoning Cancer Hospital & Institute — Shenyang, Liaoning, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.